Last reviewed · How we verify

NCT05803005

Evaluation of Some Inflammatory Markers in Autism Spectrum Disorders

Status unknown Last updated 7 April 2023
What this trial tests

trial testing inflammatory marker in autism spectrum disorder in Autism Spectrum Disorder in 100 participants. Status unknown.

Timeline
1 September 2023
Primary endpoint
1 September 2024
1 October 2024

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 September 2023
Primary completion1 September 2024
Estimated completion1 October 2024

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 3 to 18, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate some Inflammatory markers \[IL-6, IL-8, TNF\_alpha\] in children with autism spectrum disorder

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05803005.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing